CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
NCT ID: NCT05325281
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
8 participants
INTERVENTIONAL
2022-10-31
2025-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPI-613® (Dose level -1.0 250 mg/m^2)
Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
CPI-613® (Dose level -1.0 250 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
CPI-613® (Dose level 1.0 500 mg/m^2)
Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
CPI-613® (Dose level 1.0 500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
CPI-613® (Dose level 2.0 1,000 mg/m^2)
Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
CPI-613® (Dose level 2.0 1,000 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
CPI-613® (Dose level 3.0 1,500 mg/m^2)
Dose escalation/de-escalation for CPI-613® (devimistat) will be conducted using a Bayesian optimal interval (BOIN) design. Gemcitabine will be infused over 30 minutes at a fixed dose of 400 mg/m\^2 weekly. Intensity-modulated radiation therapy will be administered at 54 Gy in 30 fractions of 1.8 Gy per fraction, with five fractions given per week. CPI-613® will be given once per week by IV infusion.
CPI-613® (Dose level 3.0 1,500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
CPI-613® Maximum Tolerated Dose (MTD)
MTD of CPI-613® from initiation of treatment to 30 days after treatment. MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
CPI-613® (Dose level -1.0 250 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 1.0 500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 2.0 1,000 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 3.0 1,500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® Maximum Tolerated Dose (MTD)
MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPI-613® (Dose level -1.0 250 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 1.0 500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 2.0 1,000 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® (Dose level 3.0 1,500 mg/m^2)
CPI-613® is a mitochondrial metabolism inhibitor. CPI-613® is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.
CPI-613® Maximum Tolerated Dose (MTD)
MTD will be determined by testing increasing doses of CPI-613®, starting from 500 mg/m\^2 and up to 1,500 mg/m\^2, on dose escalation cohorts of three patients (maximum 24 patients) in combination with Gem-RT therapy. MTD reflects the highest drug dose that does not cause unacceptable adverse effects, with a target dose-limiting toxicity (DLT) rate of 30%. Final dose will be revised as appropriate.
Gemcitabine
Subjects will be administered 400 mg/m\^2 gemcitabine once per week by IV infusion over approximately 30 minutes for six weeks.
Intensity-modulated Radiation Therapy
1.8 Gy per fraction, 5 fractions per week, 30 fractions total (54 Gy) across six weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pathologically confirmed (histologic or cytologic) adenocarcinoma of the pancreas.
3. Patients should have an inoperable disease (locally advanced, oligometastatic, or medically inoperable) and, based on the review of the institutional pancreatic tumor board, should otherwise benefit from chemoradiation for definitive local control of the primary tumor.
4. Patients with and without regional adenopathy are eligible.
5. History/physical examination, including a collection of weight and vital signs, within 30 days prior to treatment.
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 14 days of study entry.
7. Imaging requirements are to include
1. Diagnostic abdominal/pelvic CT with IV contrast or abdominopelvic magnetic resonance (MR) scan with perfusion and diffusion-weighted sequences within 45 days prior to study entry.
2. Chest CT scan or X-ray within 45 days prior to study entry.
3. Radiation treatment planning abdominal CT. A recommended abdominal MR will be done as a simulation (SIM) scan with interpretation. The CT SIM will not be done with interpretation. Positron emission tomography (PET) scan and MRI are both optional but encouraged. Abdominal MR scans for staging and radiation planning and follow-up are optional but encouraged.
8. Heme Onc (Chem 24) and cancer antigen 19-9/ carcinoembryonic antigen (CEA) within 30 days prior to treatment, as follows:
1. Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3.
2. Platelets ≥ 100,000 cells/mm3.
3. Hemoglobin ≥ 8.0g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin ≥ 8.0 g/dl is acceptable).
4. Not on hemodialysis.
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \<4x the upper limit of normal.
6. Total bilirubin \<2x the upper normal mg/dL (higher levels are acceptable if Gilbert Syndrome is suspected clinically).
9. Negative serum pregnancy test (if applicable).
10. Ability to position for radiation therapy.
11. Pregnancy It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below.
Female patients must meet one of the following:
* Postmenopausal for at least one year before the screening visit, or
* Surgically sterile, or
* If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through three months after the last dose of study drug, and
* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or
* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable contraception methods.)
Male patients, even if surgically sterilized (i.e., status postvasectomy), must agree to one of the following:
* Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose, or
* Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or
* Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.)
12. Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria
2. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
3. Any major surgery within 28 days prior to study entry, except colonic stent placement, intestinal diversion without resection, exploratory laparotomy and laparoscopy or vascular access insertion.
4. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during the course of the study and for women three months after study therapy is completed and for men six months after study therapy is completed. This exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
5. Life expectancy less than two months.
6. Severe, active co-morbidity, defined as follows:
* Any unresolved bowel or bile duct obstruction, or
* Symptomatic myocardial ischemia, or
* uncontrolled clinically significant conduction abnormalities (e.g., ventricular tachycardia on antiarrhythmics is excluded and first-degree atrioventricular (AV) block or asymptomatic left anterior fascicular block (LAFB) / right bundle branch block (RBBB) will not be excluded), or
* Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
* Any active uncontrolled bleeding or patients with a bleeding diathesis.
7. Serious psychiatric illness (e.g., depression, psychosis) or medical conditions that in the opinion of investigator could interfere with treatment.
8. Concurrent therapy with approved or investigational anticancer therapeutics other that what is stipulated by the protocol.
9. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or HBsAg (HBV surface antigen).
10. Known to be HIV seropositive and on anti-HIV drugs because of the unknown interactions between these drugs and the study agents.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cornerstone Pharmaceuticals
INDUSTRY
Barbara Ann Karmanos Cancer Institute
OTHER
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mandana Kamgar, MD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mandana Kamgar, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, Hall WA, Azmi AS. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Adv Radiat Oncol. 2022 Nov 9;8(1):101122. doi: 10.1016/j.adro.2022.101122. eCollection 2023 Jan-Feb.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00043904
Identifier Type: -
Identifier Source: org_study_id